Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
Stock Information for Acer Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.